<DOC>
	<DOCNO>NCT00308360</DOCNO>
	<brief_summary>This eight-week open-label randomize parallel group clinical trial focus comparison risperidone alone risperidone plus valproate among hospitalized adult patient diagnose schizophrenia also exhibit problem hostility . Patients may already receive risperidone valproate ( ) study entry . Patients receive valproate study entry randomize receive either risperidone alone risperidone valproate . For patient already receive valproate study entry , antipsychotic medication ( ) switch risperidone , follow four-week lead-in period prior baseline assessment randomization receive risperidone alone continue risperidone valproate . We hypothesize risperidone alone antiaggressive/antihostility effect , effect augment co-administration valproate .</brief_summary>
	<brief_title>Risperidone Alone Vs. Risperidone Plus Valproate Treatment Patients With Schizophrenia Hostility</brief_title>
	<detailed_description>Background : Patients schizophrenia also exhibit hostile behavior pose formidable challenge clinician . Hostile behavior frequent reason psychiatric admission , obstacle successful reintegration patient back community . Current treatment approach generally assess control condition . Method : This eight-week open-label randomize parallel group clinical trial focus comparison risperidone alone risperidone plus valproate among hospitalized adult patient diagnose schizophrenia also exhibit problem hostility . Patients may already receive risperidone valproate ( ) study entry . Patients receive valproate study entry randomize receive either risperidone alone risperidone valproate . For patient already receive valproate study entry , antipsychotic medication ( ) switch risperidone , follow four-week lead-in period prior baseline assessment randomization receive risperidone alone continue risperidone valproate . Blinded raters complete battery assessment , include Positive Negative Syndrome Scale , Buss-Durkee Hostility Inventory , Barratt Impulsiveness Scale , Overt Aggression Scale . We hypothesize risperidone alone antiaggressive/antihostility effect , effect augment co-administration valproate .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>1 ) Male female , age 18 65 inclusive , diagnose schizophrenia ( include schizoaffective disorder ) accord DSMIV criterion use Structured Clinical Interview DSMIV Axis I Disorders ; 2 ) Referral treat psychiatrist/treatment team difficulty poor impulse control ; 3 ) At study entry subject must score least “ 3 ” ( “ mild ” ) least one follow Positive Negative Syndrome Scale item comprise activation factor : Hostility , Impulsivity , Excitement , Uncooperativeness ; 4 ) Capacity willingness give informed consent ; 5 ) Adequate knowledge English ; 6 ) Absence serious medical illness ; 7 ) Accessible , adequate vein likely permit repeat venipuncture without major problem . 1 ) Receiving adequate amount valproate risperidone time inclusion criterion meet . This define dose valproate equal exceeding 1000 mg/day ( plasma level equal great 50 micrograms/mL ) least 2 week , dose risperidone ; 2 ) History severe adverse reaction either risperidone valproate ; 3 ) Administration slowrelease antipsychotic ( depot ) within 30 day precede randomization ; 4 ) Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Hostility</keyword>
	<keyword>Impulsivity</keyword>
	<keyword>Aggression</keyword>
</DOC>